Targets › FECH
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.
Catalyzes the ferrous insertion into protoporphyrin IX and participates in the terminal step in the heme biosynthetic pathway. (UniProt, P22830)
Open in Phaseline: the race on FECH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| David W. Roberts | 5-aminolevulinic acid Prodrug that is metabolized to protoporphyrin IX (PpIX), a fluorescent porphyrin that accu | FECH | Phase 1 | Brain Tumors | Dec 2027 |
Brain Tumors (1)
small molecule (1)
David W. Roberts (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.